IL325052A - תאי t משוריינים - Google Patents
תאי t משורייניםInfo
- Publication number
- IL325052A IL325052A IL325052A IL32505225A IL325052A IL 325052 A IL325052 A IL 325052A IL 325052 A IL325052 A IL 325052A IL 32505225 A IL32505225 A IL 32505225A IL 325052 A IL325052 A IL 325052A
- Authority
- IL
- Israel
- Prior art keywords
- cancer
- cells
- population
- car
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363506586P | 2023-06-06 | 2023-06-06 | |
| PCT/IB2024/055504 WO2024252305A1 (en) | 2023-06-06 | 2024-06-05 | Armored t cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL325052A true IL325052A (he) | 2026-02-01 |
Family
ID=91581947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL325052A IL325052A (he) | 2023-06-06 | 2024-06-05 | תאי t משוריינים |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4724089A1 (he) |
| KR (1) | KR20260021025A (he) |
| CN (1) | CN121240873A (he) |
| AU (1) | AU2024285571A1 (he) |
| IL (1) | IL325052A (he) |
| MX (1) | MX2025014741A (he) |
| TW (1) | TW202511490A (he) |
| WO (1) | WO2024252305A1 (he) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024000112A (es) * | 2021-06-30 | 2024-06-19 | New York Genome Center Inc | Metodos y composiciones para inmunoterapias mejoradas. |
| US20230279352A1 (en) | 2021-08-24 | 2023-09-07 | Astrazeneca Ab | Methods for generating primary immune cells |
-
2024
- 2024-06-05 IL IL325052A patent/IL325052A/he unknown
- 2024-06-05 KR KR1020267000230A patent/KR20260021025A/ko active Pending
- 2024-06-05 CN CN202480036990.6A patent/CN121240873A/zh active Pending
- 2024-06-05 WO PCT/IB2024/055504 patent/WO2024252305A1/en not_active Ceased
- 2024-06-05 EP EP24733759.5A patent/EP4724089A1/en active Pending
- 2024-06-05 AU AU2024285571A patent/AU2024285571A1/en active Pending
- 2024-06-05 MX MX2025014741A patent/MX2025014741A/es unknown
- 2024-06-06 TW TW113121065A patent/TW202511490A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN121240873A (zh) | 2025-12-30 |
| TW202511490A (zh) | 2025-03-16 |
| MX2025014741A (es) | 2026-02-03 |
| AU2024285571A1 (en) | 2026-01-22 |
| EP4724089A1 (en) | 2026-04-15 |
| WO2024252305A1 (en) | 2024-12-12 |
| KR20260021025A (ko) | 2026-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12404314B2 (en) | Switch costimulatory receptors | |
| CN113661180B (zh) | Tn-MUC1嵌合抗原受体(CAR)T细胞疗法 | |
| US12152079B2 (en) | Nucleic acids encoding IL-13 receptor alpha 2 (IL13Ra2) chimeric antigen receptor for tumor specific T cell immunotherapy | |
| AU2015335029B2 (en) | Combination | |
| CN111601823B (zh) | 用car-t或car-nk细胞在癌症治疗中靶向lilrb4 | |
| ES2876925T3 (es) | Receptores de antígeno quiméricos específicos para ROR1 (NTRKR1) para inmunoterapia contra el cáncer | |
| JP2023081935A (ja) | がん免疫療法のための組成物および方法 | |
| TWI912312B (zh) | 用嵌合抗原受體治療癌症之組成物及方法 | |
| CN119925616A (zh) | Cd20疗法、cd22疗法和与cd19嵌合抗原受体(car)表达细胞的联合疗法 | |
| JP2024537176A (ja) | ナチュラルキラー細胞及びその使用方法 | |
| JP2023505925A (ja) | バリアント型インターロイキン-2(vIL-2)ポリペプチドをコードする腫瘍溶解性ウイルスベクター | |
| CN114630683A (zh) | 包含痘苗病毒和粒细胞生成抑制剂作为活性成分的用于治疗癌症的药物组合物 | |
| CN117247466A (zh) | 抗磷脂酰肌醇蛋白聚糖3的嵌合抗原受体及其用途 | |
| AU2024285571A1 (en) | Armored t cells | |
| KR102809807B1 (ko) | 항-cldn18.2를 포함하는 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법 | |
| KR20240012413A (ko) | 폐암 치료를 위한 조성물 및 방법 | |
| KR102739632B1 (ko) | 항-cd20 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법 | |
| WO2020097236A1 (en) | Fgl2 neutraling cell therapy and methods of use thereof | |
| CN111629737A (zh) | T细胞信号传导的miRNA调节及其应用 | |
| US20230295564A1 (en) | Galectin-9 Specific Binding Agents for Use in Treating Cancer | |
| WO2025133213A1 (en) | Death receptor 5 (dr5)-armored car-t therapeutic | |
| CN121362259A (zh) | 新型PDL1-CAR-γδT细胞的构建及其抗肿瘤应用 | |
| HK40110020A (zh) | 自然杀伤细胞及其使用方法 | |
| IL324320A (he) | תאי קטל טבעיים מרובי קולטנים |